1. (Amended) A method for selectively stimulating proliferation and differentiation of T lymphoid cells to generate a high density of clinically relevant numbers of T lymphoid cells, comprising:

collecting material comprising body fluid or tissue containing mononuclear cells from a mammal;

treating the cells under conditions whereby *ex vivo* differentiation of the cells into Th2-like or Th2 cells is induced; and

contacting, in the absence of exogenous interleukin-2, the material with two or more activating proteins specific for cell surface proteins present on cells in the material and in an amount sufficient to induce *ex vivo* cell expansion, whereby the cells expand to at least about 10^{10} cells comprising predominantly Th2 or Th2-like cells.

6. (Amended) The method of claim 1, wherein the immune cells are activated ex vivo in the presence of anti-gamma interferon, whereby differentiation of Th2 cells are effected.

79. (Amended) The method of claim 74, wherein the disease is rheumatoid arthritis, wherein the composition is produced by a method comprising:

collecting mononuclear cells from a rheumatoid arthritis patient;

expanding the cells under conditions whereby a composition containing an amount of Th2 cells sufficient to suppress or reduce the chronic inflammatory lesions of the arthritis is generated; and

infusing the resulting composition of cells into the patient.

82. (Amended) The method of claim 74, wherein the disease is multiple sclerosis, and the composition is produced by a method, comprising:

collecting mononuclear cells from a multiple sclerosis patient;

expanding the cells under conditions whereby a composition containing an amount of Th2 cells sufficient to ameliorate the symptoms or retard or stop the progression of multiple sclerosis is generated; and

infusing the resulting composition of cells into the patient.

87. (Amended) The method of claim 74, wherein the disease is an inflammatory bowel disease (IBD), and the composition is produced by a method, comprising:

collecting mononuclear cells from an IBD patient;

expanding the cells under conditions whereby a composition containing an amount of Th2 cells sufficient to ameliorate the symptoms or retard or stop the progression of the IBD; and

infusing the resulting composition of cells into the patient.

91. (Amended) The method of claim 87, wherein the Th2 cells express integrin, $\alpha 4$, $\beta 7$.

92. (Amended) A method for suppression of transplant rejection, comprising:

collecting mononuclear cells from a patient prior to undergoing organ or tissue transplantation;

expanding the cells under conditions whereby a composition containing an amount of Th2 cells sufficient to prevent rejection of the transplanted organ or tissue is generated; and

infusing the resulting composition of cells into the patient.

REMARKS

Any fees that may be due in connection with filing this paper, or with this application during its entire pendency, may be charged to Deposit Account No. 50—1213.

The specification and the claims are amended to correct obvious typographical, spelling, and formatting errors.